INTRODUCTION
The most significant morbidity resulting from congenitally deficient factor VIII or IX activity (hemophilia A or hemophilia B) is the progressive destruction of joints due to recurrent intraarticular hemorrhage. While bleeding at other sites does occur in individuals with hemophilia, the musculoskeletal system is by far the most common site. Eighty-five per cent of all bleeding events occur in joints, and 80% of these affect six problem joints: the elbows, knees and ankles. 1 Joint hemorrhage is treated by intravenous infusion of clotting factor to raise the circulating plasma activity. There is a need for adjunctive therapies directed specifically to the pathology within the hemophilic joint.
An understanding of the pathophysiology of hemophilic joint disease is only now emerging. [2] [3] [4] Joint bleeding results in a chronic inflammatory disorder known as hemophilic synovitis that in time evolves into a complex arthritis termed hemophilic arthropathy, in which the synovial disease is accompanied by degenerative changes in cartilage and underlying bone. 3, 4 As the inflammatory environment that develops in response to blood in a joint stimulates neoangiogenesis of fragile blood vessels, one or more "target" joints for recurrent bleeding develop. Joint-surface erosions secondary to chronic synovitis often occur in early childhood. 5 If aggressive early prophylactic factor replacement is not instituted, 90% of persons with severe hemophilia (<1% factor VIII or factor IX activity) will have chronic degenerative changes in one to six joints by 25 years of age.
A limited number of treatment options exist for recurrent joint bleeding and hemophilic synovitis. 6 The mainstay of therapy is replacement clotting factor dosed to achieve a circulating plasma activity level adequate to provide hemostasis throughout the body. Factor replacement in response to ongoing bleeding does not halt the progression of existing arthropathy. 5 Instead, institution of uninterrupted preventive (prophylactic) factor infusions at an early age, prior to the For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From onset of recurrent joint bleeding, should be the standard of care. 7 The major costs of hemophilia to the health care system in dollars, to society in lost productivity and to the person with hemophilia in terms of quality of life result from bleeding into joints. 8 For individuals who bleed despite systemic factor replacement adjunctive medical management is supportive, and not specific to the pathology of the hemophilic joint, e.g. systemic antiinflammatory treatment (regular narcotics; COX-2 inhibitors; intermittent systemic corticosteroids), immobilization, and physical therapy. Surgical options include ablation of the end-stage joint (joint fusion or prosthetic replacement). 2, 9, 10 There are, however, circumstances when direct local therapy to the hemophilic joint is performed. Some experienced clinicians recommend needle aspiration of the fresh blood from acutely distended and ballottable hemarthrosis; nevertheless, concurrent intra-articular injection of clotting factor has not been recommended. 2, 9, 10 For hemophilic joint bleeding that is resistant to conservative medical therapy intra-articular corticosteroids, hyaluronic acid, and chemical or radioactive compounds are examples of treatment injected directly into the joint, rather than attempts to correct the systemic coagulation system. 9, [11] [12] [13] [14] In recent years, gene therapy using AAV has been explored for the treatment of hemophilia, including hemophilia B clinical trials targeting muscle or liver. 15, 16 At the doses used (up to 2 x 10 12 vg/kg body weight into the liver) persistent hemostatic factor IX activity has not been achieved in human subjects. Compared with systemic gene therapy, intra-articular gene delivery may provide concentrated levels of the therapeutic protein within the joint, at the site of greatest risk of bleeding. The feasibility of intra-articular gene therapy has been established by several groups who have used AAV to express genes in animal models of rheumatoid arthritis and osteoarthritis (OA). [17] [18] [19] [20] [21] Nevertheless, it is unknown whether directed replacement of clotting factor
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From in synovial fluid or joint tissue can provide meaningful hemostatic protection compared to intravascular replacement.
Our investigations establish that intra-articular factor IX delivered percutaneously or via AAVmediated transduction of joint tissues decreases the progression of hemorrhage-related joint degeneration.
MATERIALS AND METHODS

AAV vector constructs and production
The AAV vector containing the 1.4 kb hFIX cDNA (rAAV-CBA-hFIX) has been described previously. 22 All vectors were produced and titered at the UNC Virus Vector Core Facility as described previously. 23 
Animal care and study
Wild type C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Factor IX knockout (FIX -/-) mice 22, 25 were bred in house. All investigations were approved by the UNC-CH Institutional Animal Care and Use Committee. Mice were anesthetized using intraperitoneal 1.25%
Avertin for all procedures. Knee joint intra-articular bleeding challenge was performed using a
Hamilton syringe with 30.5G needle via a small (~0.5 mm) incision of the skin overlying the patella For personal use only. on July 15, 2017. by guest www.bloodjournal.org From as described. 26 All blood samples were collected from the retro-orbital plexus into 1:9 parts 3.2% citrated sodium and stored at -80°C. The knee joints were collected by sectioning the femur and tibia 1-cm from the joint, fixed, and decalcified using routine histological procedures.
In vivo administration of local or systemic factor IX protein therapy 
Histologic grading of synovitis pathology
Hemophilic synovitis was graded according to a validated system, which awards 0-10 points for increasing evidence of synovial overgrowth, neovascularity, and articular bleeding (see legend, Figure 1 ). 27 Three or more independent reviewers blinded to the experimental conditions examined the entire joint space and articular surfaces of two adjacent sagittal sections from each knee. Areas of greatest synovial thickening and vascularity were identified and three nonoverlapping fields from these regions were scored at high magnification and total synovitis scores from each knee averaged. Images were captured with a DMX-1200 color camera using the Act-1 software (Nikon). 28 For personal use only. on July 15, 2017. by guest www.bloodjournal.org From
Circulating FIX after intra-articular versus intravenous delivery
To examine factor IX recovery, a single dose of 20 IU/kg IA or 20 IU/kg or 80 IU/kg IV was given and citrated plasma collected at 15min, 1hr and 2hr after injection to examine FIX recovery. To examine extended survival of FIX, both 25 IU/kg and 100 IU/kg hFIX doses were studied using IA or IV delivery. Plasma collected at 1hr, 4hr, 12hr, 24hr, 48hr, and 72hr was studied in a one-stage factor IX activity assay.
22
Detection and survival of FIX in synovial fluid after intra-articular or intravenous delivery A single dose of 100 IU/kg IA (in 5 μl total volume) or 100 IU/kg IV was given and synovial fluid was collected at 1hr, 4hr, 12hr, 24hr, 48hr and 72hr from separate cohorts (n = 6-7 mice at each timepoint). At the designated timepoint mice were sacrificed, the skin overlying the treated knee was excised, the patellar ligament dissected, and a 30.5G insulin syringe inserted into the joint capsule to instill 20 μl NS. Saline wash and synovial fluid were immediately aspirated and saved, followed by an additional 20 μl synovial lavage. 21, 29 hFIX in the combined synovial lavage fluid was measured by ELISA, as previously described. 
Bioluminescence imaging of mice
Under isoflurane anesthesia, mice were injected intraperitoneally with 150 µg/g D-luciferin in PBS.
Bioluminescence imaging with a CCD camera (IVIS, Xenogen) was initiated exactly 15 min after injection. Signal intensities from regions of interest are expressed as total photon flux (photons/s/cm2).
31
FIX activity and anti-hFIX Bethesda inhibitor assay
One-stage factor IX activity assay (FIX-specific aPTT) and factor IX Bethesda inhibitor antibody assay were performed as previously described, using a START 4 Coagulation Analyzer (Diagnostica Stago, Asnières, France). 
Statistical analysis
Quantitative data are presented as means plus or minus SD. Two-tailed paired Student's t test was performed with statistical software package (SAS v9.3). P values of <.05 were considered a statistically significant difference.
RESULTS
Development of hemophilic synovitis model in hemophilia B mice
Bleeding into the joints of hemophilic mice leads to clinical and pathological changes that closely resemble human hemophilic synovitis. Two of the authors (L.A.V. and N.H.) have previously reported the use of a blunt injury bleeding model in hemophilia A mice. 28 Similar to hemophilic joint disease followed clinically, the progression to clinically obvious joint disease in that original model could be quite variable, resulting after a single injury in some mice, or after several bleeding challenges in others. For the studies of hemostatic protection that we proposed, a model that leads to reliable bleeding-induced pathology with each injury was desired, providing the ensuing pathology could be shown to occur in hemophilic but not hemostatically normal mice. A model of more severe blood induced joint damage was characterized by the Valentino lab in factor VIII -/-mice, consisting of a single 30.5 gauge needle puncture of the knee joint capsule to induce hemarthrosis, 26 and was reported to induce similar pathology in factor IX -/-mice. 26, 33 For personal use only. 
Intra-articular FIX does not increase circulating FIX activity
We considered the possibility that, through technical error or other mechanism, the IA hFIX might enter the circulation and effect joint protection via systemic plasma activity. The circulating pharmacokinetics of plasma FIX activity were examined following hFIX dosing via the tail vein or IA. We first determined that mouse FIX and human FIX are not interchangeable in plasma. An IV dose of hFIX concentrate that would be expected to fully correct a human (80-100 IU/kg of body weight) only partially corrected the FIX -/-mouse to 10-15% activity; this was the highest dose of hFIX used in any of the treatment groups shown in Figures 1 and 2 and Previous studies have shown that FIX can be given subcutaneously, intramuscularly, or intratracheally, and via each of these routes FIX will enter the circulation in a delayed fashion when compared to intravenous delivery. 34, 35 Therefore, an extended pharmacokinetic study was performed to rule out the possibility that FIX might enter the circulation from a local "depot" after IA injection. In a control group of mice treated IV, FIX activity decayed with a half-life of 7-12 hours, consistent with previous experience in our lab and others. 36 Even using a four-fold higher IA hFIX dose than was used in the joint protection studies (Figure 1 ), no FIX activity was detected in plasma up to 72 hours after IA delivery (80 IU/kg IA; Table1-2).
Kinetics of FIX concentration within the joint space following IA and IV delivery
As neither the initial concentrations nor the survival of factor IX within the synovial space following protein therapy are known, we examined synovial fluid levels of factor IX following delivery of 100 IU/kg hFIX as either an IV or IA dose. As shown in Table1-3, hFIX entering the synovial fluid after IV delivery was near the lower limits of detection of the ELISA assay even at the earliest timepoints, whereas the plasma terminal half-life is typical for what we observe in mice (~ 6-7 hours). The initial local concentration of factor IX in synovial fluid after IA delivery was strikingly higher than the plasma level achieved from the equivalent IV dosing, however appeared to fall off rapidly in the first 12 hours. In contrast, the terminal phase fall-off in the synovial fluid closely resembled the fall-off of the intravenously delivered circulating factor IX. Therefore, the ability to localize in vivo expression using IA injection was studied using AAV vectors expressing firefly luciferase, a marker gene the expression of which could be followed serially in joints. Single strand AAV.Luciferase encapsidated in serotypes AAV2, AAV5 or AAV8 were injected into the left knee joint of adult mice at a dose of 8 × 10 8 vg/animal. Intensity and biodistribution of luciferase expression were imaged weekly. AAV2, AAV5 and AAV8 luciferase vectors all transduced joints in vivo. Expression was primarily confined to the injected joint 1 week after infection, although some luciferase expression from the AAV8 vector could be seen in extraarticular sites at that time point. By four weeks post-infection, the majority of signal from AAV8 vector came from the hepatosplenic region, at a time the other serotypes localized expression to the articular or periarticular space ( Figure 3 ).
Intra-articular delivery of AAV.hFIX: Biodistribution of expression within and outside the joint
Prior to subjecting hemophilic animals to an injury, we examined the relative biodistribution of factor IX expression from the AAV serotype vectors. AAV2-, AAV5-and AAV8-CBA-hFIX vectors were injected into the knee joints of wild type C57Bl/6 mice at the dose of 2.5× 10 9 vg/animal.
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From Four weeks later, knee joints were harvested and immunohistochemical staining for human factor IX performed. The anti-hFIX antibody does not cross-react with mouse FIX. 30 As shown in figure   4A and 4C, patterns of serotype tropism were consistent with those seen in vitro (figure S-1):
AAV5 transduced both FLS and chondrocytes, while AAV2 demonstrated a bias toward FLS transduction and AAV8 toward chondrocyte transduction. Additionally, a monoclonal anti-hFIX monoclonal antibody A-7 was used to detect hFIX in samples from the AAV8-transduced joint.
Factor IX binding by A-7 antibody depends upon the factor IX Gla-domain having at least 9-10 carboxylated glutamic acid residues. 32 The 
DISCUSSION
The data presented in these studies suggests that directing factor replacement to the hemophilic joint could yield therapeutic benefits that augment standard systemic therapy. To perform these studies in FIX -/-mice required that we establish a mouse bleeding model in which a single joint injury reliably produces in the hemophilia B animal, but not in hemostatically normal animals, the joint pathology observed in human hemarthropathy. Under the conditions tested, this model shows for the first time that clotting factor IX within the joint space protects against the development of synovitis, in the absence of measurable circulating FIX activity or protein.
Furthermore, these studies establish that persistent expression of FIX in the joint following AAV gene therapy may protect from hemophilic bleeding induced joint pathology.
Rationale for an AAV gene therapy approach to hemophilic joint arthropathy
To our knowledge, there is no published experience using intra-articular clotting factor replacement as a therapeutic strategy, probably because of 1) the general effectiveness of intravenous replacement therapy, at least in early joint disease; 2) a reluctance to potentially
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From induce injury by putting a needle into a hemophilic joint; and 3) the reasonable assumption that the site of action for thrombin generation and hemostatic plug formation must be at the intraluminal surface of the injured vessel, not in extravascular tissues. Although aspiration of the acutely distended, painful hemophilic joint following systemic factor replacement (without intraarticular clotting factor administration) is safe and can speed recovery following a severe joint hemorrhage, 2, 39 repeatedly instrumenting the joints is not feasible, especially to prevent or interrupt early joint bleeding. The ideal gene therapy strategy would direct persistent replacement of the missing coagulation factor activity within the joint. 44, 45 Given the mixed proliferative, inflammatory, degenerative features of hemophilic arthropathy, we did not wish to restrict our target for expression to either FLS or chondrocytes, exclusively; we thought it possible that therapeutic benefic might arise from expression in a variety of cell types in the joint, or even combined expression from both intra-articular and extra-articular sites. Our studies do not attempt a systematic examination of AAV serotype tropism in joint tissue. Based on experience in RA and OA applications it was expected that AAV2 and AAV5 should transduce joints, and in particular synoviocytes. This result was in fact observed in both our human joint tissue samples (Fig S-1) and in mice in vivo. (Figs. 3 and 4) The previously reported superiority of AAV5 when compared to AAV2 for joint transduction was not demonstrated using the conditions of our experiment; of the serotypes we tested, AAV5.hFIX was, however, the only one that significantly reduced synovitis at the lowest dose (2.5 x 10 9 vg/animal).
The observed AAV8 tropism was not entirely expected. In our human tissue lines and explants as well as within the hemophilic mouse joint, the AAV8 vectors appeared to be relatively specific for chondrocytes and to show minimal expression in synoviocytes, consistent with the in vitro results reported by Boissier, et al. 42 Following intra-articular delivery, AAV8 vectors displayed a natural
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From tropism for the liver in both the luciferase and FIX expression systems. Intra-articular AAV8.hFIX produced low circulating FIX levels (from <1% up to ~7% by one stage factor IX activity assay).
Despite this, the joint protection by AAV8.hFIX vector was not superior to that by AAV2 and AAV5 in this injury model. The results suggest that following intra-articular delivery of AAV-hFIX, the expressed clotting factor can concentrate within the joint space and the high localized factor levels provide joint protection that might augment or exceed the protection afforded by a lower level factor achieved by systemic gene therapy.
Extravascular clotting factor decreases development of blood induced joint pathology:
Consideration of potential mechanisms and tissue-specific hemostasis
Little is known about the extravascular coagulation potential of normal synovial fluid, despite an extensive literature about coagulation parameters in inflammatory arthritis (i.e. RA).
46-49
Osteoarthritis is considered a relatively non-inflammatory arthropathy and OA synovial fluid coagulation factors have been measured. 47, 49 Procoagulant proteins of smaller molecular weight do have significant measurable activity in OA synovial fluid (e.g. factor IX 10%, factor II 21% activity) while very large coagulants (factor V, VIII) are present at <1% of plasma activity. Chang, et. al reported that thrombin can be generated extravascularly in OA synovial fluid and that thrombin-generating potential falls off more rapidly in synovial fluid than in plasma. 50 These authors also noted that adding factor VIII or factor V in vitro rapidly enhances thrombin generation in OA synovial fluid; adding FIX was not tested in their system.
While we demonstrate that factor IX instillation or endogenous expression within the joint protects the joint from the development of synovitis and blood induced joint damage, it must be acknowledged that these studies do not allow conclusions regarding the mechanism for this protection. It can be speculated that the presence of a local concentration of FIX supports initial hemostasis of the injured joint vasculature. Although no systemic FIX activity was detectable, it is
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From possible that FIX could enter the injured vascular space from the synovial (extravascular) side to contribute to thrombin generation at the intraluminal primary platelet thrombus. Alternatively, the potential for thrombin generation within synovial fluid has been demonstrated in vitro. 50 To assume that true extravascular coagulation within the synovial space tamponades or somehow staunches the bleeding from the injured vessel, current dogma predicts that phospholipid surface would be required to form a factor Xase complex; this conceivably could be provided by platelets that enter from the injured vessel. prolonged iron deposition and macrophage infiltration than wounds of wild type mice. 51 Keeping the cutaneous wound study in mind, our detection of factor IX measured in the synovial fluid for at least 72 hours after IA delivery is intriguing (Table 1-3) . There is an initial rapid fall-off of IA factor IX, consistent with the in vitro observation of Chang, et al. of a rapid fall-off of thrombin-generating potential in synovial fluid when compared to plasma. This initial (alpha-) phase of factor IX consumption likely is influenced by collection in the setting of hemorrhage in our model. There follows a prolonged terminal (beta-) half-life of the surviving synovial fluid factor IX, which in fact differs little from the terminal kinetics of circulating factor IX in the study group treated intravenously with the same FIX dose. We further documented low and steady levels of synovial fluid factor IX at two and four weeks after gene therapy (less than 1% of the normal human factor IX level of ~5000 ng/ml plasma) in the additional group of mice treated with IA AAV5.hFIX. The
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From joint lavage method we employed certainly dilutes the samples so that an estimation of minimal protective synovial factor IX levels cannot be reached using the methods of the current study.
Nevertheless, the thrombin-generating or antifibrinolytic potential of this surviving synovial factor IX to prevent rebleeding (akin to IV prophylactic factor IX) warrants further investigation. FIX survival in the synovial fluid might not be the only mechanism for sequestration of FIX within this tissue. The synovium of joints is rich in collagen IV, 52 an endothelial extracellular matrix protein to which factor IX binds specifically. 53 There is rich vascular TF expression in sites such as cardiac muscle and the central nervous system (sites in which even minimal bleeding may be life threatening), potentially allowing rapid TF/VIIa pathway initiation, described as "tissue specific hemostasis". 54 The uninjured joint tissues and fluid have minimal vascular TF expression. 54, 55 Therefore, it is possible that sequestration of intrinsic pathway factor IX in this site (e.g. via collagen IV interaction) is a different example of tissue specific hemostasis, that protects nonhemophilic joints from hemarthropathy.
A final consideration is that IA FIX could interrupt some mediator of inflammation that promotes the inflammatory changes in the hemophilic joint. Functional TF activity is increased and TFPI decreased in inflammatory arthritis (RA) when compared to non-inflammatory arthritis (OA).
TF/VIIa activity is implicated in generating the thrombin and fibrin deposition that complicates RA, and also in stimulation of vascular smooth muscle cell migration, 46 e.g via TF/VIIa activation of Protease Activated Receptor (PAR) 2. 56 Thrombin in turn is implicated in synovial thickening 48 and proteolysis of cartilage, 57 and these processes are also central to hemophilic synovitis. To carry the example further, thrombin activates PAR 1, which can upregulate both pro-and antiinflammatory chemokines. 58, 59 One might speculate that in the absence of intrinsic pathway proteins, the regulation of the TF/VIIa/TFPI system and thrombin generation is unbalanced in a way that promotes hemophilic synovitis independently of initial hemostasis, and the balance is 60 We measured quite high initial synovial levels of factor IX after IA protein delivery to the joint. There is no evidence to suggest whether there may be risks resulting from these initially very high levels that will counter the demonstrated benefit (avoiding subacute hemophilic synovitis). Our ongoing studies evaluate this injury model and the effect of the intraarticular treatment approach upon chronic hemophilic joint pathology.
Hemophilic animal models to establish pathophysiology of bleeding-induced joint damage and joint-directed therapy
The joints of our hemophilia B mice did not have pre-existing arthropathy prior to protein or gene therapy. We are currently adapting and validating the injury model to reproduce the clinical scenario of advanced hemophilic arthropathy so as to confirm the efficacy of local factor protein or gene therapy in damaged joints. Care will need to be taken to validate a chronic arthropathy histology scale that quantitates additional endpoints for the cartilage and bone damage prevalent in chronic disease but not incorporated in the synovitis scale used in this report. After validating such a tool, the efficacy of intra-articular hemostasis in long-standing hemarthropathy deserves evaluation, as the current study can be considered to model preventive therapies in joints without preexisting disease. Several groups have now reported that inflammatory cytokines stimulated by underlying joint disease actually can increase transgene expression from AAV2 vectors. 18, 40, 61 Nevertheless, persistence of episomal transgene expression from chronically damaged joint tissues may well be limiting, and requires study. Additionally, the novel presentation of potential alloantigens (e.g. factor IX protein or vector capsid proteins) in the setting of a chronically inflamed joint could conceivably stimulate immune responses against transduced cells that were not seen in our experiments in naïve joints. 62 For personal use only. on July 15, 2017. by guest www.bloodjournal.org From Modeling bleeding-induced pathology in hemostatically normal animals (e.g. with autologous blood challenge), when compared to the hemophilic joint injury reported here or the recently reported cutaneous wound model, does not accurately reveal pathology and potential therapeutic approaches. The mouse models also enable studies with cohort sizes that cannot practically be accomplished using hemophilic canines. Confirmation of efficacy of the IA approaches in large animals will be valuable, nonetheless; the progression of hemarthropathy may depend on weightloading of the bleeding-damaged joint, with the effect increased in heavier animals. 63 In addition, gene expression using AAV serotypes has not always translated directly from mouse to large animals. 64 These investigations, documenting the capacity of IA FIX protein or gene therapy to protect the joint from bleeding-induced synovitis, suggest that joint-directed therapies may be useful adjuncts in hemophilia care, in addition to the intravascular replacement of deficient factor activity.
Additionally, the studies underscore knowledge deficits regarding tissue specific hemostasis as well as the potential intersections of coagulant proteins and inflammatory mediators within the hemophilic joint that may be explored in this model. Hemostatically normal C57BL/6 mice received intra-articular injection of 2.5×10 9 v.g. AAV2, AAV5
or AAV8 expressing hFIX into the left knee joint capsule. Four weeks later, the AAV-treated knee and untreated control knee were collected, and immunostaining performed for hFIX using polyclonal anti-FIX (A) or using monoclonal anti-factor IX A-7, specific for γ-carboxylated factor IX (B) . HRP stain appears brown in FIX-expressing cells. Hematoxylin was added as counterstain in all images. Note: FIX -/-mice were given recombinant hFIX by IV or IA at the dose of 20 IU/kg or 80 IU/kg for initial factor IX activity recovery; 25 IU/kg or 100 IU/kg for extended activity recovery. Citrated plasma was collected for FIX activity assay (aPTT) and data are presented as % of normal human plasma activity. IA, intra-articular; IV, intravenous by tail vein Note: FIX -/-mice were given recombinant hFIX by IA or IV at the dose of 100 IU/kg, n≥6 at each time point. All samples are detected via hFIX specific ELISA, reported as ng FIX/ml. SF, Synovial fluid; IA, intra-articular FIX delivery; IV, intravenous FIX delivery by tail vein; ND, not detectable. The normal circulating level of FIX protein in human plasma is 5000 ng/ml.
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